{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:17:29Z","timestamp":1786119449025,"version":"build-2736575974"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T00:00:00Z","timestamp":1767312000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,2]]},"abstract":"<jats:sec>\n                    <jats:title>Rationale:<\/jats:title>\n                    <jats:p>Clinical management of hepatitis B cirrhosis complicated with portal hypertension remains challenging. nonselective beta-blockers like carvedilol, first-line agents, have notable limitations. While simvastatin may improve liver fibrosis and reduce portal hypertension, clinical evidence \u2013 especially regarding hepatic venous pressure gradient (HVPG) \u2013 is scarce. This study investigates the efficacy and safety of simvastatin combined with antiviral therapy in patients intolerant to carvedilol.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns:<\/jats:title>\n                    <jats:p>Case 1: A 54-year-old male was admitted due to abnormal liver function for 2 weeks and fatigue with abdominal distension for 2 days. Vital signs were stable, with chronic liver disease facies, soft abdomen, positive hepatic percussion tenderness, no hepatosplenomegaly, and no ascites. Case 2: A 62-year-old male presented with intermittent fatigue for 3 months (aggravated for 1 week). His pulse rate was 49 beats per minute with mild dizziness (no chest tightness\/pain), accompanied by chronic liver disease facies, liver palms, soft abdomen, positive hepatic percussion tenderness, and no ascites or bleeding.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnoses:<\/jats:title>\n                    <jats:p>Case 1: Compensated hepatitis B cirrhosis; Portal hypertension; Carvedilol-induced bradycardia. Case 2: Compensated hepatitis B cirrhosis; Portal hypertension; Sinus bradycardia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>Basic treatment focused on HBV suppression, with portal hypertension management adjusted per contraindications and responses. Case 1 initially received carvedilol but switched to long-term simvastatin due to bradycardia. Case 2 was prescribed simvastatin upfront (given preexisting bradycardia); after self-discontinuing (HVPG increased), simvastatin was restarted for long-term maintenance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes:<\/jats:title>\n                    <jats:p>Nucleoside analogues (antiviral) plus simvastatin (reducing intrahepatic vascular resistance) effectively lowered portal venous pressure without drug-related adverse reactions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons:<\/jats:title>\n                    <jats:p>For hepatitis B cirrhosis patients with portal hypertension who are intolerant to or have contraindications for carvedilol, simvastatin combined with antiviral therapy is a safe, effective alternative. It significantly reduces HVPG, improves liver stiffness, and causes no obvious adverse events.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000046933","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T15:02:10Z","timestamp":1767711730000},"page":"e46933","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Simvastatin combined with antiviral therapy for hepatitis B cirrhosis with portal hypertension: A case report"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2697-8042","authenticated-orcid":false,"given":"Haodong","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Metabolic Hepatology, Qingdao Public Health Clinical Center, Qingdao City, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinjin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Metabolic Hepatology, Qingdao Public Health Clinical Center, Qingdao City, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Metabolic Hepatology, Qingdao Public Health Clinical Center, Qingdao City, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Metabolic Hepatology, Qingdao Public Health Clinical Center, Qingdao City, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Metabolic Hepatology, Qingdao Public Health Clinical Center, Qingdao City, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Gou","sequence":"additional","affiliation":[{"name":"Department of Metabolic Hepatology, Qingdao Public Health Clinical Center, Qingdao City, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhensheng","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Metabolic Hepatology, Qingdao Public Health Clinical Center, Qingdao City, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolong","family":"Qi","sequence":"additional","affiliation":[{"name":"Southeast University Affiliated Zhongda Hospital, Nanjing City, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260218","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","article-title":"Baveno VII - Renewing consensus in portal hypertension.","volume":"76","author":"de Franchis","year":"2022","journal-title":"J Hepatol"},{"key":"R2-20260218","first-page":"374","article-title":"Research progress on the application of carvedilol in the treatment and prevention of portal hypertension in cirrhosis patients.","volume":"31","author":"Yawei","year":"2024","journal-title":"Chin J Clin Med"},{"key":"R4-20260218","first-page":"721","article-title":"Effect of statins on the progression and prognosis of chronic liver diseases.","volume":"37","author":"Wang","year":"2021","journal-title":"J Clin Hepatol"},{"key":"R5-20260218","first-page":"402","article-title":"Mechanism and current status of simvastatin in treatment of cirrhotic portal hypertension.","volume":"35","author":"Huan","year":"2019","journal-title":"J Clin Hepatol"},{"key":"R6-20260218","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.dld.2015.07.156","article-title":"Three months of simvastatin therapy vs. placebo for severe portal hypertension in cirrhosis: a randomized controlled trial.","volume":"47","author":"Pollo-Flores","year":"2015","journal-title":"Dig Liver Dis"},{"key":"R7-20260218","first-page":"2037","article-title":"Expert consensus on multidisciplinary diagnosis and treatment of cirrhotic portal hypertension (based on hepatic venous pressure gradient).","volume":"37","author":"Lv","year":"2021","journal-title":"J Clin Hepatol"},{"key":"R8-20260218","first-page":"14","article-title":"Definition, etiology, and epidemiology of liver cirrhosis.","volume":"37","author":"Dan","year":"2021","journal-title":"J Clin Hepatol"},{"key":"R9-20260218","first-page":"457","article-title":"Guidelines for the prevention and treatment of chronic hepatitis B (version 2022).","volume":"26","author":"You","year":"2023","journal-title":"J Clin Hepatol"},{"key":"R10-20260218","first-page":"436","article-title":"Influencing factors of disease progression in patients with chronic hepatitis B treated with long-term antiviral therapy.","volume":"28","author":"Wei-Hua","year":"2023","journal-title":"Chin Hepatol"},{"key":"R11-20260218","first-page":"81","article-title":"Consensus on clinical application of hepatic venous pressure gradient in China (2023 edition).","volume":"18","author":"Wang","year":"2024","journal-title":"Chin Arch General Surg (Electronic Edition)"},{"key":"R12-20260218","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1016\/j.cgh.2015.07.012","article-title":"Varices and variceal hemorrhage in cirrhosis: a new view of an old problem.","volume":"13","author":"Garcia-Tsao","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R13-20260218","first-page":"527","article-title":"Guidelines on the management of esophagogastric variceal bleeding in cirrhotic portal hypertension.","volume":"39","author":"Yuan Xu","year":"2023","journal-title":"J Clin Hepatol"},{"key":"R14-20260218","doi-asserted-by":"crossref","first-page":"745","DOI":"10.3904\/kjim.2021.138","article-title":"Improved anti-fibrotic effects by combined treatments of simvastatin and NS-398 in experimental liver fibrosis models.","volume":"37","author":"Kang","year":"2022","journal-title":"Korean J Intern Med"},{"key":"R15-20260218","doi-asserted-by":"crossref","first-page":"166750","DOI":"10.1016\/j.bbadis.2023.166750","article-title":"Simvastatin inhibits hepatic stellate cells activation by regulating the ferroptosis signaling pathway.","volume":"1869","author":"Kitsugi","year":"2023","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"R16-20260218","doi-asserted-by":"crossref","first-page":"115644","DOI":"10.1016\/j.bcp.2023.115644","article-title":"Anti-fibrotic effects of statin drugs: a review of evidence and mechanisms.","volume":"214","author":"Dolivo","year":"2023","journal-title":"Biochem Pharmacol"},{"key":"R17-20260218","first-page":"95","article-title":"Simvastatin D with propranolol cirrhosis and portal hypertension in comparison.","volume":"31","author":"Gui Yang","year":"2012","journal-title":"China Foreign Med Treatment"},{"key":"R18-20260218","first-page":"50","article-title":"The effects of simvastatin on portal vein blood flow and liver fibrosis indexes in patients with liver cirrhosis.","volume":"16","author":"Zheng","year":"2011","journal-title":"Chin Hepatol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000046933","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:33:56Z","timestamp":1786041236000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000046933"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,2]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000046933","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,2]]},"assertion":[{"value":"2025-08-14","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-24","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}